NSE · QLINE · Trading
Q-Line Biotech Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹323 Cr with net profit ₹28 Cr — a 8.72% net margin, versus 16.68% the period before.
Shareholding
As of 2026-05-31
- Promoter67.51%
- Public20.67%
- FII1.67%
- DII10.14%
3,497 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.39× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Trading · ranked #48 of 666 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,93,641 Cr | 24.35 | 4.83 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,55,831 Cr | 388.78 | 10.45 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,60,028 Cr | 92.71 | 22.91 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹94,764 Cr | 1225.56 | 65.89 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,548 Cr | 56.79 | 6.81 | 11.32% | 6.61% |
| Premier Energies Limited | ₹45,236 Cr | 29.96 | 10.5 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹44,693 Cr | 108.92 | 7.38 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹39,129 Cr | 231.05 | 20.84 | 19.61% | 8.72% |
| Redington Limited | ₹24,837 Cr | 15.6 | 2.44 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,630 Cr | 211.1 | 10.36 | 14.16% | 8.36% |
| Q-Line Biotech Limited(this company) | ₹1,176 Cr | 20.82 | 2.41 | 22.63% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashQ-Line Biotech Limited is listed on the Indian markets with a market capitalization of Rs 1240 Cr. The company reported a revenue of Rs 322.58 Cr and an EPS of Rs 24.21. As of May 31, 2026, promoter holding stands at 67.51% and institutional holding is 11.81%.
Positives
- +Promoter holding of 67.51% as of May 31, 2026 indicates significant control.
- +The Return on Equity (ROE) is 22.63%, showing efficiency in generating shareholder returns.
- +Return on Capital Employed (ROCE) is 19.42%, reflecting efficient use of capital.
Negatives
- −The profit margin is 0%, indicating no reported profit relative to revenue.
- −Net profit decreased from Rs 34.44 Cr in March 2024 to Rs 28.13 Cr in March 2025 despite an increase in revenue.
- −The company has a debt-to-equity ratio of 0.75, which suggests a moderate level of debt.
Financial performance
Q-Line Biotech Limited's revenue increased from Rs 206.45 Cr in March 2024 to Rs 322.58 Cr in March 2025. Net profit for the same period decreased from Rs 34.44 Cr to Rs 28.13 Cr. Diluted EPS was Rs 28.63 in March 2025, compared to Rs 21.87 in March 2024.
Profitability & returns
The company reported a Return on Equity (ROE) of 22.63% and a Return on Capital Employed (ROCE) of 19.42%. The earnings per share (EPS) for the latest period was Rs 24.21. The latest profit margin is 0%.
Balance sheet
Q-Line Biotech Limited has a debt-to-equity ratio of 0.75. The book value per share is Rs 209.24. No dividend yield was reported for the company. The company's financials indicate a reliance on debt capital.
Ownership & pledges
Institutional holding combined is 11.81%. There are no reported promoter share pledges.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: May 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.